News
1d
MedPage Today on MSNIBD Biomarkers: Established Tests Are Helpful but Clinicians Want More"A diagnostic biomarker for IBD would be very impressive, but it would be even more impressive if we had a good biomarker ...
5d
MedPage Today on MSNDoublet Shows Activity in Rare, Aggressive Kidney CancerThe most common TRAEs of any grade were acneiform rash (93%), diarrhea (89%), proteinuria (78%), and dry skin (64%).
A UK biotech firm spent years gathering genetic data that has uncovered 1 million previously unknown microbial species and ...
1d
GlobalData on MSNRoche and Genentech’s Lunsumio-Polivy shows promise in Phase III trialRoche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...
Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...
Bottom line: Monday's calendar lines up two asymmetric biotech shots: If Sana's six-month data look anything like the first ...
Nebius lags CoreWeave in scale but boasts strong cash, low leverage, and diversified growth across industries. Find out why ...
Oral nicotine pouches may have potential for smoking cessation, but scientific evidence on the effects of pouches and their constituents on smoking behaviour is limited. Design This study was a 4-week ...
Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...
A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...
Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results